US 11,988,734 B2
Method and application for measuring the intracellular water transmembrane efflux rate, and measurement method and system for magnetic resonance imaging biomarker of glioma
Ruiliang Bai, Hangzhou (CN); Yinhang Jia, Hangzhou (CN); Yingchao Liu, Hangzhou (CN); and Guangxu Han, Hangzhou (CN)
Assigned to ZHEJIANG UNIVERSITY, Hangzhou (CN)
Appl. No. 18/039,709
Filed by ZHEJIANG UNIVERSITY, Hangzhou (CN)
PCT Filed Jun. 16, 2022, PCT No. PCT/CN2022/099102
§ 371(c)(1), (2) Date May 31, 2023,
PCT Pub. No. WO2023/134116, PCT Pub. Date Jul. 20, 2023.
Claims priority of application No. 202210037257.9 (CN), filed on Jan. 13, 2022; and application No. 202210666908.0 (CN), filed on Jun. 13, 2022.
Prior Publication US 2023/0349997 A1, Nov. 2, 2023
Int. Cl. G01R 33/563 (2006.01); G01R 33/56 (2006.01)
CPC G01R 33/56308 (2013.01) [G01R 33/5601 (2013.01)] 12 Claims
OG exemplary drawing
 
1. A measurement method of intracellular water transmembrane efflux rate (kio), which is not for disease diagnosis, is used as a magnetic resonance imaging biomarker to evaluate the AQP4 expression level of glioma, where in, the measurement method is:
(1) quantitatively measuring the intracellular water transmembrane efflux rate (kio), by using dynamic-contrast-enhanced magnetic resonance imaging (DCE-MRI);
(2) using a framed stereotactic biopsy technology to get biopsy tissue and quantitatively measuring its AQP4 expression level;
(3) according to kio and AQP4 expression level, establishing a linear relationship between kio and AQP4; and
(4) quantitatively re-measuring the intracellular water transmembrane efflux rate (kio) of the tissue by using dynamic-contrast-enhanced magnetic resonance imaging (DCE-MRI), and the AQP4 expression level of the tissue is obtained according to the linear relationship in step (3).